We conducted a DIA-based proteomics study for 5 patients with CHD-PBS Syndrome, 5 patients with CHD-NPBS Syndrome, and 5 healthy adults to explore the biomarkers of PBS Syndrome.
To study the mechanism underlying IDA-induced anti-tumor activity for Abi resistance, LNCaP-Abi cells were treated with Abi alone and in combination with IDA for 24 h. Protein profiles were determined by mass spectrometry
SEPHS2, a key enzyme in synthesizing selenoproteins, which converts hydrogen selenide into selenophosphate. Here we provide the proteome of SEPHS2 knockout human A375 celllines.
